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Embryonic stem cells (ESCs) transplantation is a potential
therapeutic approach for Parkinson’s disease. However,
the key problems the therapy is facing are the efficiency of
differentiation into dopaminergic (DA) neurons and the
low survival of the transplanted DA neurons. In the pre-
sent study, mouse ESC were effectively differentiated into
DA neurons by serum free method and were transplanted
into 6-OHDA lesioned striatum of PD rats. We found
reduced viability of DA neurons after graft, being accom-
panied by activated microglia and high levels of TNF-a
and iNOS. This suggested that inflammation might be an
underlying mechanism for decreased cells viability. In the
following in vitro assay, selenite, the source of essential
micronutrient selenium, was tested to inhibit inflamma-
tory activation of BV2 microglia cells. Furthermore, the
anti-inflammatory effects of selenite in animals after cells
transplantation were investigated. In PD rats treated by
selenite, microglia activation after transplantation was
inhibited in the graft niche, and the levels of TNF-a and
iNOS were effectively abated nearly by 30% and 50%. The
viability of implanted DA neurons was also remarkably
improved after selenite treatment, with favored behavior
recovery of PD rats. Therefore, selenite might benefit
embryonic stem cells therapy in Parkinson’s disease
through inhibiting inflammation.
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